Amy Zhou1, Anne Winkler2, Amir Emamifar3, Bryce Gartland1, Alexander Duncan2, Ana Antun4, Martha Arellano4, G Allen Tindol4, Jerrold H Levy5, William A Bornstein1, Ira R Horowitz6, Hanna Jean Khoury7. 1. Department of Medicine, Atlanta, GA. 2. Department of Pathology, Atlanta, GA. 3. Emory University Hospital Department of Pharmacy, Atlanta, GA. 4. Department of Hematology and Medical Oncology and the Winship Cancer Institute of Emory University, Atlanta, GA. 5. Department of Anesthesiology and Critical Care, Atlanta, GA. 6. Division of Gynecologic Oncology and the Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. 7. Department of Hematology and Medical Oncology and the Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address: hkhoury@emory.edu.
Abstract
BACKGROUND: The increased exposure to heparin products for thromboprophylaxis against VTE in hospitalized patients raises concerns for an increase in the incidence of heparin-induced thrombocytopenia(HIT). METHODS: We analyzed, among 90,875 patients exposed to heparin products between 2005 and 2009, the number of hematologic consultations for thrombocytopenia, requests for heparin induced antibodies by enzyme-linked immunosorbent assay, and cases given a diagnosis of HIT by the hematology consult service. RESULTS: We observed that despite a doubling in the number of patients receiving pharmacoprophylaxis with heparin, there was no significant increase in the number of consultations for thrombocytopenia,the number of requests for HIT tests, the number of positive HIT test results, or the number of HIT diagnoses. The number of cases of HIT was low and represented < 0.1% of patients exposed to heparin. CONCLUSIONS: We conclude that concerns about HIT should not be a limiting factor for the systematic implementation of heparin-based VTE prophylaxis.
BACKGROUND: The increased exposure to heparin products for thromboprophylaxis against VTE in hospitalized patients raises concerns for an increase in the incidence of heparin-induced thrombocytopenia(HIT). METHODS: We analyzed, among 90,875 patients exposed to heparin products between 2005 and 2009, the number of hematologic consultations for thrombocytopenia, requests for heparin induced antibodies by enzyme-linked immunosorbent assay, and cases given a diagnosis of HIT by the hematology consult service. RESULTS: We observed that despite a doubling in the number of patients receiving pharmacoprophylaxis with heparin, there was no significant increase in the number of consultations for thrombocytopenia,the number of requests for HIT tests, the number of positive HIT test results, or the number of HIT diagnoses. The number of cases of HIT was low and represented < 0.1% of patients exposed to heparin. CONCLUSIONS: We conclude that concerns about HIT should not be a limiting factor for the systematic implementation of heparin-based VTE prophylaxis.
Authors: Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz Journal: JCI Insight Date: 2018-09-20